Valeant's ($VRX) tender offer for Allergan ($AGN) isn't expiring just yet. The company has extended the deadline to Dec. 31, giving it and activist investor partner Bill Ackman a few more months to go after deal-averse Allergan. At least one supporter is betting heavily that the Canadian pharma can pull the deal off: Paulson & Co. acquired 5.6 million shares of Allergan valued at nearly $1 billion during the second quarter, Bloomberg reports. News (sub. req.) | More